Plasma Biomarkers P-DAC, V1
Identification of Predictive Plasma Biomarkers in Pancreatic Ductal Adenocarcinoma (PDAC Plasma Biomarker Study)
Sponsor: Cancer Trials Ireland
Terminated
As per the HRBs new funding model, HRBs investment will not support costs associated with routine patient care or translational studies, biobanks, patient registries and questionnaires. Therefore, a decision was made to cease further study follow up.
Other terminated trials from Cancer Trials Ireland
Other Pancreatic Ductal Adenocarcinoma trials with similar outcome
Listed as NCT02050997, this observational or N/A phase trial focuses on Pancreatic Ductal Adenocarcinoma and remains terminated or withdrawn. Sponsored by Cancer Trials Ireland, it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Aug 2025 — Present [monthly]
Terminated
-
Sep 2024 — Aug 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
May 2023 — Jul 2024 [monthly]
Terminated
-
Feb 2022 — May 2023 [monthly]
Terminated
Status: Active Not Recruiting → Terminated
▶ Show 8 earlier versions
-
Mar 2021 — Feb 2022 [monthly]
Active Not Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Feb 2020 [monthly]
Recruiting
-
Aug 2018 — Aug 2019 [monthly]
Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Trials Ireland
For direct contact, visit the study record on ClinicalTrials.gov .